GLP1R and chronic kidney disease: The aim of this study is to evaluate the real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1RA) in patients with newly diagnosed Type 2 diabetes (T2DM), particularly among those with high cardiovascular risks or chronic kidney disease, and to identify demographic, clinical, and system-level factors associated with receiving these medications.